Danaher to Buy Abcam in $5.7 Billion Deal
By Colin Kellaher
Life-sciences giant Danaher has agreed to buy Abcam, a supplier of protein consumables, in a deal carrying a total enterprise value of about $5.7 billion, including assumed debt.
Danaher on Monday said it would pay $24 a share in cash for Abcam, a scant 2.7% premium to Friday's closing price of $23.36 for the U.K.-based company.
Danaher said Abcam will operate as a standalone company and brand within its life-sciences segment, furthering its strategy to help map complex diseases and accelerate the drug-discovery process.
Washington-based Danaher said it plans to fund the deal, slated to close in mid-2024, with cash on hand and proceeds from the issuance of commercial paper.
Trading in shares of Abcam was halted premarket on Monday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 28, 2023 07:58 ET (11:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks
-
After Earnings, Is Disney Stock a Buy, a Sell, or Fairly Valued?
-
Home Depot Earnings: Macro Factors Pinch Demand, but Long-Term Outlook Intact